{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/otitis-media-acute/prescribing-information/co-amoxiclav/","result":{"pageContext":{"chapter":{"id":"bb1b0220-4609-5ab7-8102-e31414c36dab","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":2,"htmlHeader":"<!-- begin field abd713b8-a76d-43f9-b00d-a74c00d0ee67 --><h2>Co-amoxiclav</h2><!-- end field abd713b8-a76d-43f9-b00d-a74c00d0ee67 -->","summary":"","htmlStringContent":"<!-- begin item 16cf523c-b3b3-4516-9b13-a74c00d0edac --><!-- end item 16cf523c-b3b3-4516-9b13-a74c00d0edac -->","topic":{"id":"0671aacb-4e00-5bb2-8b54-aa0da27fb4ab","topicId":"009f13e7-d649-401b-8b63-061c029e67f2","topicName":"Otitis media - acute","slug":"otitis-media-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"793c7288-db92-5c67-8ef6-0ea9a20f6b09","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0cbb536b-178c-5bea-a1c6-22c584a7e1b6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"944570b9-0a8f-5b67-8ee8-556c3fd8a613","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"aedad1bf-9c58-57d9-9c3d-d1fa6e40ee13","slug":"changes","fullItemName":"Changes"},{"id":"7bc4152c-a9f8-5afe-bb63-2a48a86ebf0d","slug":"update","fullItemName":"Update"}]},{"id":"cd84410b-569d-58a4-8fe8-c2eaed2ead26","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7875d022-7cbf-5961-a19e-d5987af92edc","slug":"goals","fullItemName":"Goals"},{"id":"8db5ac64-8db5-5daa-aa3c-d46caaf0abf3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3517d1cc-7aae-5036-81f5-ac0b590e84fd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4ca0ace8-77fc-5319-95e0-e983fa092ed9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f87cf2b3-b0ea-5485-b424-9518a3f586a2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e285c16b-d4ba-56b6-a3fd-3c27fc822357","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"749e39ba-56ce-5129-8e10-fef140b586c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9df3117d-949e-56bb-ac40-0393fb87071a","slug":"definition","fullItemName":"Definition"},{"id":"cb42b641-fdc3-5bd6-a13a-ca2c1edd9c21","slug":"causes","fullItemName":"Causes"},{"id":"2682b3f3-3099-54c9-9c02-867b7f3350e0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a7d4a184-6baa-5ae6-baef-11eba15038e6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"fc412f0f-261f-5fae-a125-cfeefdd5e8b3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"18e296ab-cfe3-58be-bf23-aaf4a6c6f49e","slug":"complications","fullItemName":"Complications"}]},{"id":"a0da1ac3-73ef-561b-9301-a1ccdf5fd8a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9e9b0e14-9f7d-5c5a-83a1-c4bfd193ba3d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"7e76e099-c70a-5f57-b670-c0ad43913066","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0dac3638-3899-5899-bd0e-647894c3f003","fullItemName":"Management","slug":"management","subChapters":[{"id":"35db78a7-148c-5b20-8fd7-54ea5aaba599","slug":"acute-otitis-media-initial-presentation","fullItemName":"Scenario: Acute otitis media - initial presentation"},{"id":"4d27de1d-1fe0-5438-98c0-f85415825ca5","slug":"persistent-acute-otitis-media-treatment-failure","fullItemName":"Scenario: Persistent acute otitis media - treatment failure"},{"id":"7d848f0c-bb0a-5ea7-90f2-dd99a1cbc49e","slug":"recurrent-acute-otitis-media","fullItemName":"Scenario: Recurrent acute otitis media"}]},{"id":"c8285b67-3320-54ae-8537-4c0626e3632e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f512abb6-f15e-5fef-9f9d-23e008c401ff","slug":"analgesia","fullItemName":"Analgesia"},{"id":"15d20ee0-531c-5230-9e41-6194bfbe3614","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"859385d7-8fde-5b5e-8357-c34d3500eeb7","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"bb1b0220-4609-5ab7-8102-e31414c36dab","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"0f55a4d8-b11d-53a6-a26e-b2a9e98e8dd8","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"f43bc1b4-a67e-5bab-b27c-d141e7483b01","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"51596c5b-15a7-547d-bdcf-f7a467961cd7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f91fb8f9-4942-5683-8b3d-d8edd775f700","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c2fdf612-fff8-581e-bf78-7c9efcf08ddf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2bb0e3c7-8948-5401-97a7-741ffa1d4477","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"570abb9c-faad-515e-86bb-0b947414dcb9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5e5c540f-ce64-5768-9c46-dfde85f5364a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7f9af8df-6314-54fa-a769-b5bd0bd121ab","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c8285b67-3320-54ae-8537-4c0626e3632e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6aed150e-59b4-5c56-84d9-8768df950fae","slug":"dosing-regime","fullItemName":"Dosing regime","depth":3,"htmlHeader":"<!-- begin field 5d97cf6d-b89f-4861-9c5c-a74c00d1b039 --><h3>Dosing regime</h3><!-- end field 5d97cf6d-b89f-4861-9c5c-a74c00d1b039 -->","summary":"","htmlStringContent":"<!-- begin item 9cd33f2d-8918-4a65-9ed8-a74c00d1afd4 --><!-- begin field d9292393-ae08-4e53-bd16-a74c00d1b039 --><ul><li><strong>The treatment duration for acute otitis media is 5–7 days.</strong></li><li>Prescribe: <ul><li>Child 1–11 months: 0.25 mL/kg of 125/31 suspension three times a day.</li><li>Child 1–5 years: 5 mL of 125/31 suspension three times a day<em> or</em> 0.25 mL/kg of 125/31 suspension three times a day.</li><li>Child 6–11 years: 5 mL of 250/62 suspension three times a day<em> or</em> 0.15 mL/kg of 250/62 suspension three times a day.</li><li>Child 12–17 years: 250/125 mg or 500/125 mg three times a day.</li></ul></li><li><strong>In children with renal impairment:</strong><ul><li>If the estimated glomerular filtration rate (eGFR) is 10–30 mL/minute/1.73 m<sup>2</sup>, prescribe the normal dose every 12 hours.</li><li>If the eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>, use the normal dose recommended for mild to moderate infections every 12 hours.</li></ul></li><li><strong>In adults,</strong> prescribe one 250/125 strength tablet three times a day; increased in severe infections to one 500/125 strength tablet three times a day.</li><li><strong>In adults with renal impairment:</strong><ul><li>If the eGFR is 10–30 mL/minute/1.73 m<sup>2</sup>, prescribe one 250/125 strength tablet every 12 hours <em>or</em> one 500/125 strength tablet every 12 hours.</li><li>If the eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>, prescribe one 250/125 strength tablet every 24 hours <em>or</em> one 500/125 strength tablet every 24 hours.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]</p><!-- end field d9292393-ae08-4e53-bd16-a74c00d1b039 --><!-- end item 9cd33f2d-8918-4a65-9ed8-a74c00d1afd4 -->","subChapters":[]},{"id":"9f7f0ebc-b692-5335-8d1b-9593ee4e824d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field fca0a8a2-071c-4c13-a07a-a74c00d1c37b --><h3>Contraindications and cautions</h3><!-- end field fca0a8a2-071c-4c13-a07a-a74c00d1c37b -->","summary":"","htmlStringContent":"<!-- begin item ae26c090-4600-4c76-bc07-a74c00d1c27b --><!-- begin field 7fe00184-f6c5-4a34-8278-a74c00d1c37b --><ul><li><strong>Do not prescribe co-amoxiclav in people with:</strong><ul><li>A <em>true </em>penicillin allergy — allergic reactions to penicillins occur in 1–10% of exposed individuals; anaphylactic reactions occur in fewer than 0.05% of treated patients.<ul><li>Gastrointestinal adverse effects alone (for example, nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li></ul></li><li>A hypersensitivity to cephalosporins — there is some evidence of partial cross-allergenicity. </li><li>A history of co-amoxiclav-associated or penicillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution in people with:</strong><ul><li>Hepatic impairment – monitor closely.</li><li>Chronic kidney disease (CKD) — reduce the dose if the estimated glomerular filtration rate (eGFR) is 30 mL/minute/1.73 m<sup>2</sup> or less.</li><li>Acute lymphocytic leukaemia, chronic lymphocytic leukaemia, cytomegalovirus infection, glandular fever — increased risk of erythematous rashes.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>]</p><!-- end field 7fe00184-f6c5-4a34-8278-a74c00d1c37b --><!-- end item ae26c090-4600-4c76-bc07-a74c00d1c27b -->","subChapters":[]},{"id":"ae157166-c43c-5a88-80c6-6633f484c3cd","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field bd92e5ce-0bb8-4847-8493-a74c00d1d2c2 --><h3>Adverse effects</h3><!-- end field bd92e5ce-0bb8-4847-8493-a74c00d1d2c2 -->","summary":"","htmlStringContent":"<!-- begin item 0d544226-48e8-40e5-a29b-a74c00d1d248 --><!-- begin field 1e7dca26-8801-4881-ac05-a74c00d1d2c2 --><ul><li><strong>Gastrointestinal </strong>— nausea and vomiting (common), diarrhoea (very common), antibiotic associated colitis (frequency unknown).</li><li><strong>Nervous system</strong> — headache, dizziness (uncommon).</li><li><strong>Skin</strong> — skin rash, urticaria and pruritus (uncommon), drug reaction with eosinophilia and systemic symptoms (DRESS) (frequency unknown).<ul><li><strong>Rarely:</strong> erythema multiforme.</li><li><strong>Frequency unknown:</strong> Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis and acute generalised exanthematous pustulosis.</li></ul></li><li><strong>Other rare, or very rare adverse effects, or those for which the frequency is not known include:</strong><ul><li>Hepatitis, cholestatic jaundice.</li><li>Convulsions.</li><li>Hypersensitivity reactions (serious and occasionally fatal).  </li><li>Interstitial nephritis.</li><li>Leucopenia, thrombocytopenia, haemolytic anaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>]</p><!-- end field 1e7dca26-8801-4881-ac05-a74c00d1d2c2 --><!-- end item 0d544226-48e8-40e5-a29b-a74c00d1d248 -->","subChapters":[]},{"id":"73e597f9-d1e8-5ed6-a719-18368973f833","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c322b7ac-8d7f-44f6-90fb-a74c00d1e2cd --><h3>Drug interactions</h3><!-- end field c322b7ac-8d7f-44f6-90fb-a74c00d1e2cd -->","summary":"","htmlStringContent":"<!-- begin item aca00edd-5ffd-420e-af0a-a74c00d1e1bd --><!-- begin field cede5cf1-fe9a-4b1e-9e0f-a74c00d1e2cd --><ul><li><strong>Allopurinol</strong> — concomitant use of allopurinol and amoxicillin may increase the incidence of skin rashes.</li><li><strong>Methotrexate </strong>— co-amoxiclav may reduce methotrexate clearance, causing an increased risk of toxicity.<ul><li>Monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected. </li></ul></li><li><strong>Mycophenolate mofitil</strong> — reduction in the level of active metabolite may occur when given with co-amoxiclav.</li><li><strong>Oral anticoagulants (warfarin, phenindione) </strong>— prolongation of international normalised ratio has been reported in people taking penicillins and warfarin concurrently.<ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the anticoagulant dose may be necessary.</li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of co-amoxiclav.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li><li><strong>Probenecid </strong>— concomitant administration may result in increased levels of amoxicillin, but not clavulanic acid.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>]</p><!-- end field cede5cf1-fe9a-4b1e-9e0f-a74c00d1e2cd --><!-- end item aca00edd-5ffd-420e-af0a-a74c00d1e1bd -->","subChapters":[]},{"id":"8a792539-34cf-5b99-8af8-c9eb2cd40fd8","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 39da342e-c3d6-4d7e-9066-a74c00d1f4a2 --><h3>Pregnancy and breastfeeding</h3><!-- end field 39da342e-c3d6-4d7e-9066-a74c00d1f4a2 -->","summary":"","htmlStringContent":"<!-- begin item 70173f76-f31b-4f20-9198-a74c00d1f3d4 --><!-- begin field 74bfb65a-0f3c-4d73-a700-a74c00d1f4a2 --><h4>Pregnancy</h4><ul><li>Co-amoxiclav is not known to be harmful in pregnancy, but the manufacturer advises avoidance of use during pregnancy unless considered essential.</li></ul><h4>Breastfeeding</h4><ul><li>Trace amounts of co-amoxiclav are found in breastmilk and it may cause diarrhoea or fungal infection of mucous membranes in the infant.<ul><li>Penicillins (and cephalosporins) are the antibiotics of choice in women who are breastfeeding.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Kearney, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>]</p><!-- end field 74bfb65a-0f3c-4d73-a700-a74c00d1f4a2 --><!-- end item 70173f76-f31b-4f20-9198-a74c00d1f3d4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}